scholarly journals Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study

Author(s):  
Selda Murat ◽  
◽  
Hakki Kaya ◽  
Yuksel Cavusoglu ◽  
Mehmet Birhan Yilmaz ◽  
...  
2019 ◽  
Vol 26 (4) ◽  
pp. 90-101 ◽  
Author(s):  
L. G. Voronkov ◽  
A.V. Liashenko ◽  
N. A. Tkach ◽  
L. P. Paraschenyuk

Regulatory, structural and functional disturbances of other organs and systems (kidney, hepar, vessels, skeletal muscles, brain etc) play the substantial role in CHF. These disturbances may be the conseguences of pre-existing states (hypertension, diabetes, hypo- or hyperthyreoidism etc) and from, other side, may reflect the progressive inherent changes in chronic heart failure (CHF) per se. In particular, currently relevant comorbidities in this syndrome are insulin resistance, diabetes mellitus, renal dysfunction, cognitive impairment, depression peripheral myopathy. Every of them demonstrate the close pathophysiologic interplay with CHF which results in clinical prognosis impairment and in decrease of life quality. Prevalence of renal dysfunction described in 39 % of patients with CHF in our research. Renal dysfunction connected with older age, high class of NYHA, diabetes mellitus, arterial hypertension, higher level of citrulline and uric acid in patients with CHF. Patients with iron deficiency characterized with high class of NYHA, low functionality and poor quality of life. In patients with iron deficiency noted high level of mortality and many critical clinical events. Prevalence of cognitive impairment described in 85 % of patients with CHF in our research. Cognitive dysfunction associated with older age, high class of NYHA, diabetes mellitus, arterial hypertension, bad life quality, high level of ceruloplasmin in patients with CHF. Taking to account above-mentioned comorbidities in quideline-recommended management of CHF and the use of additional therapeutic approaches targeted to its treatment represent the contemporary strategy of personalized treatment in this syndrome.


2020 ◽  
Vol 22 (2) ◽  
pp. 181-188
Author(s):  
E.V. Efremova ◽  
◽  
A.M. Shutov ◽  
A.S. Podusov ◽  
M.P. Markevich ◽  
...  

2019 ◽  
Vol 19 (20) ◽  
pp. 1818-1849 ◽  
Author(s):  
Ban Liu ◽  
Yuliang Wang ◽  
Yangyang Zhang ◽  
Biao Yan

: Type 2 diabetes mellitus is one of the most common forms of the disease worldwide. Hyperglycemia and insulin resistance play key roles in type 2 diabetes mellitus. Renal glucose reabsorption is an essential feature in glycaemic control. Kidneys filter 160 g of glucose daily in healthy subjects under euglycaemic conditions. The expanding epidemic of diabetes leads to a prevalence of diabetes-related cardiovascular disorders, in particular, heart failure and renal dysfunction. Cellular glucose uptake is a fundamental process for homeostasis, growth, and metabolism. In humans, three families of glucose transporters have been identified, including the glucose facilitators GLUTs, the sodium-glucose cotransporter SGLTs, and the recently identified SWEETs. Structures of the major isoforms of all three families were studied. Sodium-glucose cotransporter (SGLT2) provides most of the capacity for renal glucose reabsorption in the early proximal tubule. A number of cardiovascular outcome trials in patients with type 2 diabetes have been studied with SGLT2 inhibitors reducing cardiovascular morbidity and mortality. : The current review article summarises these aspects and discusses possible mechanisms with SGLT2 inhibitors in protecting heart failure and renal dysfunction in diabetic patients. Through glucosuria, SGLT2 inhibitors reduce body weight and body fat, and shift substrate utilisation from carbohydrates to lipids and, possibly, ketone bodies. These pleiotropic effects of SGLT2 inhibitors are likely to have contributed to the results of the EMPA-REG OUTCOME trial in which the SGLT2 inhibitor, empagliflozin, slowed down the progression of chronic kidney disease and reduced major adverse cardiovascular events in high-risk individuals with type 2 diabetes. This review discusses the role of SGLT2 in the physiology and pathophysiology of renal glucose reabsorption and outlines the unexpected logic of inhibiting SGLT2 in the diabetic kidney.


2017 ◽  
Vol 21 (4) ◽  
pp. 15-20
Author(s):  
Elena A Andreeva ◽  
Marina A Pokhaznikova ◽  
Irina E Moiseeva ◽  
Olga Yu Kuznetsova ◽  
Jean-Marie Degryse

The article presents an analysis of the risk factors for anxiety and depression in people with airflow limitation based on the results of the second (diagnostic) phase of the RESPECT (RESearch on the PrEvalence and the diagnosis of COPD and its Tobacco-related aetiology). The data indicates that participants with airflow limitation that had been revealed during the epidemiological study and with borderline or abnormal anxiety and/or depression showed in diagnostic study persistent airflow limitation (FEV1/FVC = 66.48 ± 10.22, p < 0.05) and more perceived respiratory symptoms (CAT = 11.1 ± 10.01, mMRC = 1.68 ± 1.02, p < 0.001) compared to those without mental disorders. Also, they tended to have concomitant cardiovascular diseases (coronary heart disease, chronic heart failure, p < 0.001) and diabetes mellitus (p < 0.01) more frequently. Although chronic heart failure is the most prominent risk factor for anxiety/depression, it becomes non-significant when corrected for other somatic diseases and respiratory symptoms.


2020 ◽  
Vol 11 (2) ◽  
pp. 394-404 ◽  
Author(s):  
Jack O. Garnham ◽  
Lee D. Roberts ◽  
Ever Espino‐Gonzalez ◽  
Anna Whitehead ◽  
Peter P. Swoboda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document